The PARADIGM-HF trial randomized 8442 patients with symptomatic HF and a left ventricular ejection fraction ≤40% to the ACE inhibitor enalapril or to the combination of the angiotensin-receptor blocker valsartan and the neprilysin inhibitor sacubitril9. The gene discussed is ACE; the disease is hydrops fetalis.